Fig. 2
From: Modeling antibody drug conjugate potential using a granzyme B antibody fusion protein
GrBmut-TRA target binding and GrB activity. A ELISA determination of TRA, T-DM1, and GrBmut-TRA binding to immobilized HER2 or irrelevant protein at various concentrations. B Assessment of TRA, T-DM1, and GrBmut-TRA binding to HER2-expressing (B16, SK-OV-3, SK-BR-3) and non-expressing (B16) cell lines by flow cytometry. C Enzymatic activity of GrB was determined through absorbance using a GrB-specific chromogenic substrate (Ac-IEPD-pNA). Abbreviations used: CI, 95% confidence intervals; ECD, extracellular domain; GrB, granzyme B; rGrB, recombinant GrB; GrB-TRA, catalytically active AFP with WT GrB; GrBmut-TRA, catalytically active AFP with mutated GrB; SA, specific activity; T-DM1, ado-trastuzumab emtansine; TRA, trastuzumab. Bars ± STDEV. Select results are based on technical replicates of 3 samples per treatment group. Individual data values are provided in supplementary information (Additional file 2)